Neotigason (Acitretin)

Acitretin binds to retinoic acid receptors (RAR) and retinoid X receptors (RXR) in the cell nucleus. This interaction modifies gene expression that controls keratinocyte differentiation and proliferation, leading to reduced epidermal hyperplasia and improved skin appearance.

The dose of Neotigason is individualized by the prescribing clinician based on disease severity, patient weight, and laboratory monitoring. Only a qualified healthcare professional should determine the appropriate regimen.

Neotigason is classified as pregnancy category X because it is highly teratogenic. It should not be used by pregnant women or women who may become pregnant. Breastfeeding is not recommended while taking acitretin, as it can be excreted in milk.

To order Neotigason, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with systemic agents such as methotrexate, acitretin offers a non‑immunosuppressive option that primarily targets keratinocyte differentiation. Unlike biologics, it does not require injection and has a different safety profile, but it carries risks of teratogenicity, liver toxicity, and lipid abnormalities that must be monitored.

Neotigason tablets should be stored at ambient temperature below 25 °C, in the original packaging, protected from moisture and light. Keep the product out of reach of children and avoid storing in humid or excessively hot environments.

Neotigason is taken orally as a tablet, usually with a full glass of water. It may be taken with or without food, depending on the prescriber’s advice, and should be swallowed whole, not crushed or chewed.

The most serious risks include severe liver injury, acute pancreatitis, marked hyperlipidaemia, skeletal toxicity such as premature epiphyseal closure, and teratogenic effects. Patients should report any signs of liver dysfunction, abdominal pain, or unusual bone pain to their healthcare provider promptly.

Neotigason should not be used by pregnant women, women of childbearing potential who are not using reliable contraception, children and adolescents with active growth plates, patients with severe hepatic impairment, or anyone with known hypersensitivity to acitretin or other retinoids.